Background
Material and methods
Data source
Study design, study population, and intervention
Covariates
Statistical analyses
Results
Study population in the primary analysis
Patient characteristics before PSW | Patient characteristics (%) after PSWa | |||||
---|---|---|---|---|---|---|
CCT (n = 103) | Without CCT (n = 265) | Standardized differenceb | CCT | Without CCT | Standardized differenceb | |
Number (%)b or mean (SD)b | Number (%)b or mean (SD)b | |||||
Age (years) | ||||||
≤ 58 | 53 (51) | 139 (52) | 0.020 | 50 | 50 | ≈ 0 |
> 58 | 50 (49) | 126 (48) | 50 | 50 | ||
Gender | ||||||
Female | 5 (5) | 12 (5) | 0.015 | 5 | 5 | ≈ 0 |
Male | 98 (95) | 253 (95) | 95 | 95 | ||
Residency | ||||||
Non-north | 77 (75) | 185 (70) | 0.111 | 73 | 73 | ≈ 0 |
North | 26 (25) | 80 (30) | 27 | 27 | ||
Comorbidity | ||||||
Without | 91 (88) | 233 (88) | 0.013 | 89 | 89 | ≈ 0 |
Withc | 12 (12) | 32 (12) | 11 | 11 | ||
BMI (kg/m2) | ||||||
≤ 18.5 | 22 (21) | 62 (23) | 0.049 | 21 | 21 | ≈ 0 |
> 18.5 | 81 (79) | 203 (77) | 79 | 79 | ||
Drinking | ||||||
No | 14 (14) | 46 (17) | 0.104 | 14 | 14 | ≈ 0 |
Yes | 89 (86) | 219 (83) | 86 | 86 | ||
Smoking | ||||||
No | 10 (10) | 43 (16) | 0.195 | 11 | 11 | ≈ 0 |
Yes | 93 (90) | 222 (84) | 89 | 89 | ||
Grade | ||||||
Poorly | 34 (33) | 59 (22) | 0.242 | 30 | 30 | ≈ 0 |
Well/moderately differentiated | 69 (67) | 206 (78) | 70 | 70 | ||
Tumor location | ||||||
Upper | 56 (54) | 97 (37) | 50 | 50 | ||
Middle | 34 (33) | 122 (46) | 0.269 | 36 | 36 | ≈ 0 |
Lower | 13 (13) | 46 (17) | 0.133 | 14 | 14 | ≈ 0 |
Tumor size (cm) | ||||||
≤ 5 cm | 43 (42) | 99 (37) | 0.090 | 41 | 41 | ≈ 0 |
> 5 cm | 60 (58) | 166 (63) | 59 | 59 | ||
Clinical T-stage | ||||||
T1–T2 | 10 (10) | 32 (12) | 0.076 | 10 | 10 | ≈ 0 |
T3–T4 | 93 (90) | 233 (88) | 90 | 90 | ||
Clinical N-stage | ||||||
N0 | 9 (9) | 23 (9) | 0.002 | 9 | 9 | ≈ 0 |
N1-N2 | 94 (91) | 242 (91) | 91 | 91 | ||
Clinical stage | ||||||
II | 11 (11) | 30 (11) | 0.020 | 12 | 12 | ≈ 0 |
III | 92 (89) | 235 (89) | 88 | 88 | ||
Reason for no surgery | ||||||
Without contraindication | 99 (96) | 248 (94) | 0.115 | 95 | 95 | ≈ 0 |
With contraindication | 4 (4) | 17 (6) | 5 | 5 | ||
RT modality | ||||||
3DCRT | 7 (7) | 7 (3) | 0.197 | 5 | 5 | ≈ 0 |
IMRT | 96 (93) | 258 (97) | 95 | 95 | ||
Use of PET | ||||||
No | 45 (44) | 77 (29) | 0.308 | 37 | 37 | ≈ 0 |
Yes | 58 (56) | 188 (71) | 63 | 63 | ||
RT break | ||||||
≤ 1 week | 79 (77) | 197 (74) | 0.055 | 76 | 76 | ≈ 0 |
> 1 week | 24 (23) | 68 (26) | 24 | 24 | ||
RT dose | ||||||
Low | 25 (24) | 88 (33) | 0.198 | 26 | 26 | ≈ 0 |
High | 78 (76) | 177 (67) | 74 | 74 | ||
Induction chemotherapy | ||||||
Without | 98 (95) | 258 (97) | 0.117 | 96 | 96 | ≈ 0 |
With | 5 (5) | 7 (3) | 4 | 4 |
Primary analysis
Supplementary analyses (SA-1, SA-2)
CCT (n = 91) | Without CCT (n = 91) | Standardized differencea | |||
---|---|---|---|---|---|
Number or mean (SD)a | (%)a | Number or mean (SD)a | (%)a | ||
Age (years) | |||||
≤ 58 | 47 | (52) | 44 | (48) | 0.066 |
> 58 | 44 | (48) | 47 | (52) | |
Gender | |||||
Female | 5 | (5) | 3 | (3) | 0.107 |
Male | 86 | (95) | 88 | (97) | |
Residency | |||||
Non-north | 66 | (73) | 70 | (77) | 0.101 |
North | 25 | (27) | 21 | (23) | |
Comorbidity | |||||
Without | 79 | (87) | 83 | (91) | 0.141 |
Withb | 12 | (13) | 8 | (9) | |
BMI (kg/m2) | |||||
≤ 18.5 | 20 | (22) | 14 | (15) | 0.170 |
> 18.5 | 71 | (78) | 77 | (85) | |
Drinking | |||||
No | 13 | (14) | 15 | (16) | 0.061 |
Yes | 78 | (86) | 76 | (84) | |
Smoking | |||||
No | 10 | (11) | 10 | (11) | 0 |
Yes | 81 | (89) | 81 | (89) | |
Grade | |||||
Poorly | 28 | (31) | 23 | (25) | 0.123 |
Well/moderately differentiated | 63 | (69) | 68 | (75) | |
Tumor location | |||||
Upper | 46 | (51) | 44 | (48) | |
Middle | 32 | (35) | 35 | (39) | 0.068 |
Lower | 13 | (14) | 12 | (13) | 0.032 |
Tumor size (cm) | |||||
≤ 5 cm | 38 | (42) | 43 | (47) | 0.111 |
> 5 cm | 53 | (58) | 48 | (53) | |
Clinical T-stage | |||||
T1–T2 | 10 | (11) | 9 | (10) | 0.036 |
T3–T4 | 81 | (89) | 82 | (90) | |
Clinical N-stage | |||||
N0 | 9 | (10) | 8 | (9) | 0.038 |
N1–N2 | 82 | (90) | 83 | (91) | |
Clinical stage | |||||
II | 11 | (12) | 10 | (11) | 0.034 |
III | 80 | (88) | 81 | (89) | |
Reason for no surgery | |||||
Without contraindication | 87 | (96) | 87 | (96) | 0 |
With contraindication | 4 | (4) | 4 | (4) | |
RT modality | |||||
3DCRT | 6 | (7) | 3 | (3) | 0.152 |
IMRT | 85 | (93) | 88 | (97) | |
Use of PET | |||||
No | 34 | (37) | 36 | (40) | 0.045 |
Yes | 57 | (63) | 55 | (60) | |
RT break | |||||
≤ 1 week | 69 | (76) | 70 | (77) | 0.026 |
> 1 week | 22 | (24) | 21 | (23) | |
RT dose | |||||
Low | 23 | (25) | 22 | (24) | 0.025 |
High | 68 | (75) | 69 | (76) | |
Induction chemotherapy | |||||
Without | 87 | (96) | 86 | (95) | 0.051 |
With | 4 | (4) | 5 | (5) |
Patient characteristics before PSW | Patient characteristics (%) after PSWa | |||||
---|---|---|---|---|---|---|
CCT (n = 79) | Without CCT (n = 167) | Standardized differenceb | CCT | Without CCT | Standardized differenceb | |
Number (%)b or mean (SD)b | Number (%)b or mean (SD)b | |||||
Age (years) | ||||||
≤ 58 | 42 (53) | 90 (54) | 0.015 | 51 | 51 | ≈ 0 |
> 58 | 37 (47) | 77 (46) | 49 | 49 | ||
Gender | ||||||
Female | 4 (5) | 7 (4) | 0.042 | 5 | 5 | ≈ 0 |
Male | 75 (95) | 160 (96) | 95 | 95 | ||
Residency | ||||||
Non-north | 60 (76) | 119 (71) | 0.107 | 74 | 74 | ≈ 0 |
North | 19 (24) | 48 (29) | 26 | 26 | ||
Comorbidity | ||||||
Without | 69 (87) | 146 (87) | 0.003 | 88 | 88 | ≈ 0 |
Withc | 10 (13) | 21 (13) | 12 | 12 | ||
BMI (kg/m2) | ||||||
≤ 18.5 | 15 (19) | 36 (22) | 0.064 | 19 | 19 | ≈ 0 |
> 18.5 | 64 (81) | 131 (78) | 81 | 81 | ||
Drinking | ||||||
No | 11 (14) | 22 (13) | 0.022 | 14 | 14 | ≈ 0 |
Yes | 68 (86) | 145 (87) | 86 | 86 | ||
Smoking | ||||||
No | 8 (10) | 20 (12) | 0.059 | 11 | 11 | ≈ 0 |
Yes | 71 (90) | 147 (88) | 89 | 89 | ||
Grade | ||||||
Poorly | 25 (32) | 40 (24) | 0.172 | 31 | 31 | ≈ 0 |
Well/moderately differentiated | 54 (68) | 127 (76) | 69 | 69 | ||
Tumor location | ||||||
Upper | 43 (54) | 65 (39) | 50 | 50 | ||
Middle | 25 (32) | 75 (45) | 0.275 | 35 | 35 | ≈ 0 |
Lower | 11 (14) | 27 (16) | 0.063 | 15 | 15 | ≈ 0 |
Tumor size (cm) | ||||||
≤ 5 cm | 34 (43) | 61 (37) | 0.133 | 43 | 43 | ≈ 0 |
> 5 cm | 45 (57) | 106 (63) | 57 | 57 | ||
Clinical T-stage | ||||||
T1–T2 | 7 (9) | 17 (10) | 0.045 | 8 | 8 | ≈ 0 |
T3–T4 | 72 (91) | 150 (90) | 92 | 92 | ||
Clinical N-stage | ||||||
N0 | 7 (9) | 8 (5) | 0.162 | 7 | 7 | ≈ 0 |
N1–N2 | 72 (91) | 159 (95) | 93 | 93 | ||
Clinical stage | ||||||
II | 9 (11) | 14 (8) | 0.101 | 10 | 10 | ≈ 0 |
III | 70 (89) | 153 (92) | 90 | 90 | ||
Reason for no surgery | ||||||
Without contraindication | 75 (95) | 154 (92) | 0.111 | 94 | 94 | ≈ 0 |
With contraindication | 4 (5) | 13 (8) | 6 | 6 | ||
RT modality | ||||||
3DCRT | 7 (9) | 4 (2) | 0.283 | 5 | 5 | ≈ 0 |
IMRT | 72 (91) | 163 (98) | 95 | 95 | ||
Use of PET | ||||||
No | 34 (43) | 42 (25) | 0.384 | 35 | 35 | ≈ 0 |
Yes | 45 (57) | 125 (75) | 65 | 65 | ||
RT break | ||||||
≤ 1 week | 63 (80) | 125 (75) | 0.117 | 79 | 79 | ≈ 0 |
> 1 week | 16 (20) | 42 (25) | 21 | 21 | ||
RT dose | ||||||
Low | 19 (24) | 54 (32) | 0.185 | 26 | 26 | ≈ 0 |
High | 60 (76) | 113 (68) | 74 | 74 | ||
Induction chemotherapy | ||||||
Without | 74 (94) | 162 (97) | 0.159 | 95 | 95 | ≈ 0 |
With | 5 (6) | 5 (3) | 5 | 5 |